Skip to content
Screener

Penumbra PEN Embolization and Access — Revenue

Other product segments

Embolization and Other
$455.75M+20.2%
Thrombectomy
$253.92M+12.1%

Similar metrics at other companies

Teladoc Health logo
TDOCAccess Fees — Revenue
$474.22M-9.4%
Oshkosh logo
OSKAccess — Revenue
$1.37B+9.4%
Strattec Security logo
STRTPower Access Solutions — Revenue
$33.48M-8.3%
ADTRAN Holdings, Inc. logo
ADTNAccess Aggregation Solutions — Revenue
$90.52M+1.6%
Oshkosh logo
OSKOther Access Equipment — Revenue
$375.4M+28.2%
Ethan Allen Interiors logo
ETDAccent — Revenue
$24.99M-10.1%

Other financials

Income statement

See full
Revenue$374.8M+15.6%
Gross profit$253.4M+17.4%
Operating income$38.2M-5.2%
Net income$32.6M-16.9%
EPS (diluted)$0.82-18.0%

Balance sheet

See full
Cash & equivalents$241.3M-35.8%
Total debt$216.2M-2.0%
Total equity$1.5B+21.5%
Total assets$1.9B+19.2%

Cash flow

See full
Operating cash flow$87.0M+77.6%
CapEx$13.7M+1.5%
Free cash flow$73.3M+106%

Valuation

See full
Market cap$12.73B+36.0%
Enterprise value$12.71B+38.7%
P/E74.4×+11.1×
P/S8.8×+1.4×

Profitability

See full
Gross margin67.4%+3.7pp
Operating margin12.9%+9.8pp
Net margin11.8%+8.4pp
FCF margin14.6%+2.5pp

Returns & leverage

See full
Return on equity12.7%+9.2pp
Debt / equity0.1×0.0×
Current ratio6×-0.3×

Where this comes from

Reported directly by Penumbra in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Penumbra’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:45 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001321732-26-000019
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Thrombectomy$253,917$226,544
Embolization and Access120,84197,596
Total$374,758$324,140

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Penumbra's embolization and access — revenue?
Penumbra (PEN) reported embolization and access — revenue of $120.84M in Q1 2026.
How has Penumbra's embolization and access — revenue changed year-over-year?
Penumbra's embolization and access — revenue increased by 23.8% year-over-year, from $97.6M to $120.84M.
What does embolization and access — revenue mean?
This metric represents the total revenue generated from the sale of medical devices specifically designed for neurovascular embolization and vascular access procedures. It captures the financial performance of the product line used by physicians to navigate the vasculature and treat complex neurovascular conditions. This revenue stream is a critical indicator of the company's market penetration in specialized neurosurgical and interventional radiology segments.

Ask your AI about Penumbra's embolization and access — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude